Crestor
Grünenthal buys European rights to AstraZeneca’s Crestor for a potential $350m
December 1, 2020Manufacturing and Production, Sales and Marketing AstraZeneca, Crestor, Grunenthal
Grünenthal has picked up AstraZeneca’s statin therapy Crestor (rosuvastatin), currently approved in dyslipidaemia and hypercholesterolaemia treatment, in a deal worth …
AstraZeneca loses legal bid to block Crestor generics
July 20, 2016Research and Development, Sales and Marketing AstraZeneca, Crestor, FDA, generics, legal
A US district court judge has refused AstraZeneca’s request for a temporary restraining order blocking the approval of generic versions …
AstraZeneca files suit to block FDA from approving copies of cholesterol drug Crestor
July 11, 2016Sales and Marketing AstraZeneca, Crestor, US FDA, patent, regulation
Anglo-Swedish drug firm AstraZeneca (LSE: AZN) has filed a temporary restraining order to prevent the US Food and Drug Administration from …
Allergan launches Crestor generic in the US
May 3, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, AstraZeneca, Crestor, FDA, FDA Approval, cholesterol, generic, patent, patent expiry, sales
Allergan has received FDA approval on the generic version of AstraZeneca’s high cholesterol drug, Crestor (rosuvastatin), and has become the …
AZ warns of patent losses as revenues fall
February 4, 2016Medical Communications, Sales and Marketing AstraZeneca, Crestor, Zurampic
AstraZeneca announced full-year revenues down 7% to $24.7 billion, and Q4 sales down 5% to $6.4 billion, as the London-based …
More changes at the top as AstraZeneca profits slip
November 1, 2013Sales and Marketing AstraZeneca, Crestor, Q3, profits
AstraZeneca’s third quarter revenues and profits fell below analysts’ expectations yesterday, but mitigated the news with the appointment of a …
AstraZeneca settles Crestor case
March 26, 2013Sales and Marketing AstraZeneca, Crestor, Watson
AstraZeneca has settled a long-running legal battle over one of its biggest brands, Crestor, whose patent expires in 2016. The …
Shionogi opens UK office
July 9, 2012Research and Development, Sales and Marketing Crestor, Japan, Osaka, Shionogi, cholesterol
Japanese pharma firm Shionogi & Co has opened a new office in London and pledged to expand into Europe. Osaka-based …
Crestor fails head-to-head test against Lipitor
September 2, 2011Sales and Marketing Crestor, Lipitor
AstraZeneca’s cholesterol drug Crestor has failed to show it can stop artery disease better than Pfizer’s Lipitor. The new study …
Caution raised on statins in healthy people
January 20, 2011Sales and Marketing Cochrane, Crestor, Lipitor, statin, statin prescribing
Researchers have warned of a lack of evidence to support prescribing statins in patients at low risk of developing heart …
Patent expiries bite into AstraZeneca revenues
October 29, 2010Sales and Marketing AstraZeneca, Crestor, Q3, Seroquel
Generic competition and a major drop off in pandemic influenza products saw AstraZeneca’s revenue fall for the third quarter. Revenue …
Watson submits Crestor copycat
October 28, 2010Sales and Marketing AstraZeneca, Crestor, Watson, generic, patent
Watson Pharmaceuticals is seeking to launch a generic version of AstraZeneca cholesterol blockbuster Crestor, exploiting weaknesses in its patent. The …
Crestor victory lifts AstraZeneca
July 1, 2010Sales and Marketing AstraZeneca, Crestor
AstraZeneca has defeated a challenge to the US patent on its blockbuster cholesterol drug Crestor. A US District Judge in …
Crestor gains prevention licence in Europe
April 27, 2010Sales and Marketing AstraZeneca, Crestor, statin
AstraZeneca’s statin treatment Crestor has been approved in the European Union for the prevention of major cardiovascular events in patients …
